1. Home
  2. VYNE vs BAFN Comparison

VYNE vs BAFN Comparison

Compare VYNE & BAFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VYNE Therapeutics Inc.

VYNE

VYNE Therapeutics Inc.

HOLD

Current Price

$0.68

Market Cap

22.3M

Sector

Health Care

ML Signal

HOLD

Logo BayFirst Financial Corp.

BAFN

BayFirst Financial Corp.

HOLD

Current Price

$6.39

Market Cap

26.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
VYNE
BAFN
Founded
2003
1999
Country
United States
United States
Employees
10
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Savings Institutions
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
22.3M
26.6M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
VYNE
BAFN
Price
$0.68
$6.39
Analyst Decision
Hold
Analyst Count
1
0
Target Price
N/A
N/A
AVG Volume (30 Days)
232.7K
73.0K
Earning Date
05-08-2026
04-30-2026
Dividend Yield
N/A
1.00%
EPS Growth
33.33
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.29
$4.80
52 Week High
$1.96
$16.35

Technical Indicators

Market Signals
Indicator
VYNE
BAFN
Relative Strength Index (RSI) 66.11 37.60
Support Level $0.56 $5.75
Resistance Level $0.69 $7.08
Average True Range (ATR) 0.02 0.65
MACD 0.00 -0.15
Stochastic Oscillator 88.82 20.69

Price Performance

Historical Comparison
VYNE
BAFN

About VYNE VYNE Therapeutics Inc.

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.

Share on Social Networks: